<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5008809</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0161256</article-id><article-id pub-id-type="publisher-id">PONE-D-16-04421</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Metastasis</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Basic Cancer Research</subject><subj-group><subject>Metastasis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene Expression</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Colorectal Cancer</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Signal transduction</subject><subj-group><subject>Cell signaling</subject><subj-group><subject>Signaling cascades</subject><subj-group><subject>MAPK signaling cascades</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Molecular biology</subject><subj-group><subject>Molecular biology techniques</subject><subj-group><subject>Sequencing techniques</subject><subj-group><subject>RNA sequencing</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Molecular biology techniques</subject><subj-group><subject>Sequencing techniques</subject><subj-group><subject>RNA sequencing</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Molecular Biology</subject><subj-group><subject>Molecular Biology Techniques</subject><subj-group><subject>Cloning</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Molecular Biology Techniques</subject><subj-group><subject>Cloning</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Signal transduction</subject><subj-group><subject>Cell signaling</subject><subj-group><subject>Signaling cascades</subject><subj-group><subject>TGF-beta signaling cascade</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Metabolism</subject><subj-group><subject>Metabolic Pathways</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>The Genome-Wide Analysis of Carcinoembryonic Antigen Signaling by Colorectal Cancer Cells Using RNA Sequencing</article-title><alt-title alt-title-type="running-head">Transcriptome Analysis of Carcinoembryonic Antigen Producing Cancer Cells</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7506-4736</contrib-id><name><surname>Bajenova</surname><given-names>Olga</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>Gorbunova</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Evsyukov</surname><given-names>Igor</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rayko</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gapon</surname><given-names>Svetlana</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bozhokina</surname><given-names>Ekaterina</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Shishkin</surname><given-names>Alexander</given-names></name><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>O&#x02019;Brien</surname><given-names>Stephen J.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label><addr-line>Theodosius Dobzhansky Center for Genome Bioinformatics, St. Petersburg State University, St. Petersburg, Russia</addr-line></aff><aff id="aff002"><label>2</label><addr-line>Department of Genetics and Biotechnology, St. Petersburg State University, St. Petersburg, Russia</addr-line></aff><aff id="aff003"><label>3</label><addr-line>Institute of Cytology RAS, St. Petersburg, Russia</addr-line></aff><aff id="aff004"><label>4</label><addr-line>Boston Children&#x02019;s Hospital, Boston, MA, United States of America</addr-line></aff><aff id="aff005"><label>5</label><addr-line>Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, California, United States of America</addr-line></aff><aff id="aff006"><label>6</label><addr-line>Oceanographic Center, 8000 N. Ocean Drive, Nova Southeastern University, Ft Lauderdale, Florida, 33004, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Ulasov</surname><given-names>Ilya</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Swedish Neuroscience Institute, UNITED STATES</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p><list list-type="simple"><list-item><p><bold>Conceived and designed the experiments:</bold> OB SJO.</p></list-item><list-item><p><bold>Performed the experiments:</bold> OB AS SG IE AG EB.</p></list-item><list-item><p><bold>Analyzed the data:</bold> OB IE MR AS AG.</p></list-item><list-item><p><bold>Contributed reagents/materials/analysis tools:</bold> OB SJO AS EB SG AG.</p></list-item><list-item><p><bold>Wrote the paper:</bold> OB SJO IE AG MR EB.</p></list-item></list>
</p></fn><corresp id="cor001">* E-mail: <email>obajen@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>1</day><month>9</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>11</volume><issue>9</issue><elocation-id>e0161256</elocation-id><history><date date-type="received"><day>12</day><month>4</month><year>2016</year></date><date date-type="accepted"><day>2</day><month>8</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; 2016 Bajenova et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Bajenova et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0161256.pdf"/><abstract><p>&#x00421;arcinoembryonic antigen (CEA, CEACAM5, CD66) is a promoter of metastasis in epithelial cancers that is widely used as a prognostic clinical marker of metastasis. The aim of this study is to identify the network of genes that are associated with CEA-induced colorectal cancer liver metastasis. We compared the genome-wide transcriptomic profiles of CEA positive (MIP101 clone 8) and CEA negative (MIP 101) colorectal cancer cell lines with different metastatic potential <italic>in vivo</italic>. The CEA-producing cells displayed quantitative changes in the level of expression for 100 genes (over-expressed or down-regulated). They were confirmed by quantitative RT-PCR. The KEGG pathway analysis identified 4 significantly enriched pathways: cytokine-cytokine receptor interaction, MAPK signaling pathway, TGF-beta signaling pathway and pyrimidine metabolism. Our results suggest that CEA production by colorectal cancer cells triggers colorectal cancer progression by inducing the epithelial- mesenchymal transition, increasing tumor cell invasiveness into the surrounding tissues and suppressing stress and apoptotic signaling. The novel gene expression distinctions establish the relationships between the existing cancer markers and implicate new potential biomarkers for colorectal cancer hepatic metastasis.</p></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100002261</institution-id><institution>Russian Foundation for Basic Research</institution></institution-wrap></funding-source><award-id>11-04-01711</award-id><principal-award-recipient><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7506-4736</contrib-id><name><surname>Bajenova</surname><given-names>Olga</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution>the Government of the Russian Federation mega grant</institution></funding-source><award-id>11G34.31.0068</award-id><principal-award-recipient><name><surname>O'Brien</surname><given-names>Stephen James J.</given-names></name></principal-award-recipient></award-group><funding-statement>This work was financially supported by the Russian Foundation for Fundamental Research, grant RFFI # 11-04-01711 to OB, by the Government of the Russian Federation mega grant 11G34.31.0068 to SO. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="3"/><page-count count="10"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Intestinal cancers rank fourth in cancer incidence in the world. Despite the improvement of early diagnostics, 20% of primary colorectal cancer diagnoses reveal remote metastases. Available therapies still offer a poor prognosis and patients have a less than 10% five year survival rate [<xref rid="pone.0161256.ref001" ref-type="bibr">1</xref>]. The serum CEA test is recommended by the American Society of Clinical Oncology [<xref rid="pone.0161256.ref002" ref-type="bibr">2</xref>] and by the European Group on Tumor Markers [<xref rid="pone.0161256.ref003" ref-type="bibr">3</xref>] as a prognostic and postoperative marker for metastases and as an aid in the management of cancer patients. Clinical efficacy of CEA screening has been demonstrated in the follow-up management of patients with colorectal, breast, lung, prostate, pancreatic and ovarian carcinoma [<xref rid="pone.0161256.ref004" ref-type="bibr">4</xref>].</p><p>CEA is a large glycoprotein (~180 kD), a member of the <italic>Carcinoembryonic antigen</italic> gene family and the immunoglobulin (Ig) gene superfamily and comprises an exceptionally diverse array of highly glycosylated glycoproteins <ext-link ext-link-type="uri" xlink:href="http://www.carcinoembryonic-antigen.de/index.html">http://www.carcinoembryonic-antigen.de/index.html</ext-link> [<xref rid="pone.0161256.ref005" ref-type="bibr">5</xref>]. <italic>CEACAM</italic> genes are expressed in multiple cell types including epithelial, endothelial and immune cells such as leukocytes and dendritic cells. CEACAM molecules are generally inserted into the cell membrane via a transmembrane domain or physically linked to membrane via glycosyl-phosphatidylinositol anchorage [<xref rid="pone.0161256.ref005" ref-type="bibr">5</xref>]. Regulation of intercellular adhesion is a major function of CEA [<xref rid="pone.0161256.ref006" ref-type="bibr">6</xref>] and CEA can establish and maintain tissue architecture and function in the colon. The tumorigenic effects of CEA include inhibiting cell differentiation, blocking cell polarization, distorting tissue architecture and inhibiting anoikis (cell death due to the loss of cell-cell contacts) [<xref rid="pone.0161256.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0161256.ref008" ref-type="bibr">8</xref>]. Nonetheless, the molecular mechanism of CEA related metastasis is not well understood.</p><p>We used 2 human colorectal derived MIP101 cell lines of the same origin with a different metastatic potential [<xref rid="pone.0161256.ref009" ref-type="bibr">9</xref>] to study the influence of CEA on metastasis. Original low-differentiated, poorly metastatic MIP101 cell lines do not produce CEA. The derivative MIP101-clone 8 was genetically modified by transfection with a construct contaning the full-length <italic>CEA</italic> gene and a G418 antibiotic resistance selected to express CEA.</p><p>Here we measured transcriptome differences induced by CEA production in colorectal cancer cells with differing levels of CEA production and metastatic potential. The RNA sequencing technology (RNAseq) allows for the comparison of RNA produced by different cell lines, estimation of the level of gene expression, and identification of changes in gene splicing and in the signaling pathways that are involved in response to CEA over-expression.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and Methods</title><sec id="sec003"><title>Cell Culture</title><p>MIP101 is the CEA-negative cell line and MIP 101 clone 8 is the CEA-positive cell line. Both cell lines are generous gift from Dr. P. Thomas of Creighton University, Omaha, NE. The MIP 101 clone 8 cell line was produced by transfection of MIP-101 with the full-length CEA cDNA and was selected by culturing the cells in the presence of G 418 (Thermo Scientific, Lafayette, CA, USA). The cell lines were cultured under the same conditions in a sterile incubator at 37 degrees C in a liquid RPMI (Invitrogen Life Technologies, CA) medium with supplements on Petri dishes until 70&#x02013;80% of the confluence. The RPMI 1640 (Invitrogen Life Technologies, CA) medium was supplemented with 10% fetal bovine serum (FBS; Hyclone, Thermo Scientific, Lafayette, CA, USA), 100tte, CA, USAA,ntifiSigma-Aldrich, St. Louis, MO, USA), 100Aldrich, St. Louis, MSigma-Aldrich, St. Louis, MO, USA), and 300ich, St. Louis, MOSigma-Aldrich, St. Louis, MO, USA) at 37ldrich, St. Lo<sub>2</sub> atmosphere. Cells were trypsinized and counted. Over 10 million cells from each strain were collected by centrifugation. Two cell lines were cultured in two replicates.</p></sec><sec id="sec004"><title>RNA Isolation and Sequencing</title><p>Total RNA was extracted from human colon carcinoma cells using Trizol reagent, according to the manufacturer's protocol (Invitrogen Life Technologies, CA) and cleared from ribosomal RNA. Poly-(A)RNA were isolated from 3 mg of total RNA using Sera-Mag oligo (dT) spheres (Thermo Scientific, Lafayette, CA, USA).</p><p>Libraries for sequencing were obtained using the Truseq kit, universal adapter sequences, and specific PCR primers, recommended by Illumina. (Illumina, SanDiego, CA, USA). The mRNA sequencing libraries were prepared and sequenced using an Illumina HiSeq2000 instrument at the Broad Institute, Boston, USA. More than 50 M reads were produced for each library with read length of 76 bp.</p></sec><sec id="sec005"><title>Transcriptome analysis</title><p>We tested sequence reads using the quality control program FastQC (<ext-link ext-link-type="uri" xlink:href="http://www.bioinformatics.babraham.ac.uk/projects/fastqc/">http://www.bioinformatics.babraham.ac.uk/projects/fastqc/</ext-link>) [<xref rid="pone.0161256.ref010" ref-type="bibr">10</xref>]. Reads were cleaned using FASTX-Toolkit (<ext-link ext-link-type="uri" xlink:href="http://hannonlab.cshl.edu/fastx_toolkit/">http://hannonlab.cshl.edu/fastx_toolkit/</ext-link>) to remove the low-quality reads and traces of Illumina adapter sequences.</p><p>Clean reads were mapped to the GRCh37 human reference genome using TopHat (v2.0.9) as part of a Tuxedo pipeline [<xref rid="pone.0161256.ref011" ref-type="bibr">11</xref>]. The expression level for the genes and their isoforms were calculated by Cufflinks and resulted in FPKM values (fragments per kilobase of exon per million fragments mapped). Differential expression levels between samples were calculated by EdgeR package [<xref rid="pone.0161256.ref012" ref-type="bibr">12</xref>], and the p-value was adjusted using the FDR (false discovery rate) control method. EdgeR package is based on the statistical method quantile-adjusted conditional maximum likelihood estimator for the dispersion parameter of the negative binomial distribution which was developed for very small sample sizes, typical of those from analysis of gene expression studies with small number of observations (e.g. 2 libraries for a given experimental condition) [<xref rid="pone.0161256.ref012" ref-type="bibr">12</xref>]. The genes were considered differentially expressed between two conditions if they showed a log2 fold-change ratio more than 2 and displayed an FDR-adjusted p-value &#x0003c;0.05. We identified relevant biological processes and molecular pathways using the Gene Set Enrichment Analysis (GSEA) tool (<ext-link ext-link-type="uri" xlink:href="http://www.broadinstitute.org/gsea">http://www.broadinstitute.org/gsea</ext-link>).</p></sec><sec id="sec006"><title>Validation of RNA-sequencing data by qRT-PCR</title><p>Using the Primer 3 program (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/tools/primer-blast/">http://www.ncbi.nlm.nih.gov/tools/primer-blast/</ext-link>) PCR primers were designed to be suitable for all significant isoforms of each differentially expressed gene; forward and reverse primers were located in different exons of the corresponding gene (<xref ref-type="supplementary-material" rid="pone.0161256.s004">S3 Table</xref>). The sequences of the selected primers shown in the <xref ref-type="supplementary-material" rid="pone.0161256.s004">S3 Table</xref> were used, the expression levels of the <italic>CEA</italic> and <italic>GAPDH</italic> genes were used as controls for PCR analysis. Each qRT-PCR reaction was performed with three replicates.</p></sec></sec><sec sec-type="results" id="sec007"><title>Results</title><sec id="sec008"><title>Global Gene Expression Profiling by RNA sequencing</title><p>To analyze the changes of transcriptome associated with CEA up-regulation, we compared global transcript levels in the CEA-up-regulated (MIP101 clone 8) and CEA negative (MIP101) cell lines using the Tophat pipeline [<xref rid="pone.0161256.ref010" ref-type="bibr">10</xref>, <xref rid="pone.0161256.ref011" ref-type="bibr">11</xref>]. One hundred transcripts of known genes were significantly different in expression. 32 genes were up-regulated and 68 were down-regulated in CEA-producing cells having a fold change in expression &#x0003e;2 and FDR &#x0003c; 0.05 (<xref ref-type="supplementary-material" rid="pone.0161256.s002">S1 Table</xref>). The top 30 up-regulated and down-regulated genes with an FDR &#x0003c; 0.0001 are summarized in <xref ref-type="fig" rid="pone.0161256.g001">Fig 1</xref>.</p><fig id="pone.0161256.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0161256.g001</object-id><label>Fig 1</label><caption><title>The top 30 upregulated and downregulated genes in CEA+ and CEA- cells.</title><p>The red color indicates upregulated mRNA; the blue color indicates downregulated mRNA. On the right side of the square are the names of the genes that differ in the expression between MIP101 (CEA-) and MIP101 clone 8 (CEA +) cell lines. The experiments were performed in two replicates starting from RNA extraction. As a control, we performed an analysis of the <italic>CEA</italic> gene and its isoforms expression level in these cell lines by RNA-seq data. <xref ref-type="fig" rid="pone.0161256.g002">Fig 2</xref> shows plots of the <italic>CEA</italic> expression. Expression of the <italic>CEA</italic> gene is present in the CEA-producing line (MIP101 clone 8) and absent in the CEA-deficient cell line (MIP101). Moreover, CEA gene was represented by one isoform <italic>CEACAM5-001</italic> (<xref ref-type="fig" rid="pone.0161256.g002">Fig 2B</xref>).</p></caption><graphic xlink:href="pone.0161256.g001"/></fig><fig id="pone.0161256.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0161256.g002</object-id><label>Fig 2</label><caption><title>Differential expression analysis results for <italic>CEA (CEACAM5)</italic> gene.</title><p>a. Expression plot shows differences in the <italic>CEACAM5</italic> expression level between MIP101 (CEA-, blue color) and MIP101 clone 8 (CEA+, brown color) cell lines, measured in FPKM. Each sample was represented by two replicates. b. Expression level of <italic>CEACAM5</italic> is represented by single <italic>CEACAM5-001</italic> isoform.</p></caption><graphic xlink:href="pone.0161256.g002"/></fig></sec><sec id="sec009"><title>Molecular Pathways and Biological Processes Analysis</title><p>In order to identify putative biological processes affected by changes in gene expression, we performed Gene Ontology enrichment analysis using the Gene Set Enrichment Analysis (GSEA) tool (<ext-link ext-link-type="uri" xlink:href="http://www.broadinstitute.org/gsea">http://www.broadinstitute.org/gsea</ext-link>). 49 biological processes were functionally enriched including cell proliferation and apoptosis in response to stress and other cancer-related processes. The top 10 identified biological processes are summarized in <xref ref-type="table" rid="pone.0161256.t001">Table 1</xref> and the complete list is presented in the <xref ref-type="supplementary-material" rid="pone.0161256.s003">S2 Table</xref>.</p><table-wrap id="pone.0161256.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0161256.t001</object-id><label>Table 1</label><caption><title>Top 10 functional enriched GO biological processes regulated by CEA expression level in MIP101 colorectal cancer cells.</title></caption><alternatives><graphic id="pone.0161256.t001g" xlink:href="pone.0161256.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Gene ontology term ID</th><th align="left" rowspan="1" colspan="1">Term name</th><th align="left" colspan="2" rowspan="1">P-value</th><th align="left" rowspan="1" colspan="1">FDR q-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">GO:0008283</td><td align="left" colspan="2" rowspan="1">Cell proliferation</td><td align="left" rowspan="1" colspan="1">5.67E-09</td><td align="left" rowspan="1" colspan="1">2.20E-06</td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0006915</td><td align="left" colspan="2" rowspan="1">Apoptosis</td><td align="left" rowspan="1" colspan="1">1.87E-07</td><td align="left" rowspan="1" colspan="1">2.47E-05</td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0006950</td><td align="left" colspan="2" rowspan="1">Response to stress</td><td align="left" rowspan="1" colspan="1">7.40E-06</td><td align="left" rowspan="1" colspan="1">5.09E-04</td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0008544</td><td align="left" colspan="2" rowspan="1">Epidermis development</td><td align="left" rowspan="1" colspan="1">1.21E-05</td><td align="left" rowspan="1" colspan="1">7.67E-04</td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0007398</td><td align="left" colspan="2" rowspan="1">Ectoderm development</td><td align="left" rowspan="1" colspan="1">1.94E-05</td><td align="left" rowspan="1" colspan="1">1.14E-03</td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0050793</td><td align="left" colspan="2" rowspan="1">Regulation of developmental process</td><td align="left" rowspan="1" colspan="1">2.65E-05</td><td align="left" rowspan="1" colspan="1">1.46E-03</td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0007165</td><td align="left" colspan="2" rowspan="1">Signal transduction</td><td align="left" rowspan="1" colspan="1">8.28E-05</td><td align="left" rowspan="1" colspan="1">4.02E-03</td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0006350</td><td align="left" colspan="2" rowspan="1">Transcription</td><td align="left" rowspan="1" colspan="1">1.19E-04</td><td align="left" rowspan="1" colspan="1">5.46E-03</td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0009888</td><td align="left" colspan="2" rowspan="1">Tissue development</td><td align="left" rowspan="1" colspan="1">1.63E-04</td><td align="left" rowspan="1" colspan="1">6.37E-03</td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0006139</td><td align="left" colspan="2" rowspan="1">Nucleotide and nucleic acid metabolic process</td><td align="left" rowspan="1" colspan="1">1.64E-04</td><td align="left" rowspan="1" colspan="1">6.37E-03</td></tr></tbody></table></alternatives></table-wrap><p>Molecular pathways regulated by CEA over-expression were identified by pathway analysis using Kyoto Encyclopedia of Genes and Genomes (KEGG). In total, we identified 4 significantly overrepresented pathways: cytokine-cytokine receptor interaction, MAPK signaling pathway, TGF-beta signaling pathway and pyrimidine metabolism (see <xref ref-type="table" rid="pone.0161256.t002">Table 2</xref>).</p><table-wrap id="pone.0161256.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0161256.t002</object-id><label>Table 2</label><caption><title>Molecular pathway analysis of genes regulated by CEA expression level in MIP101 cells by KEGG database.</title></caption><alternatives><graphic id="pone.0161256.t002g" xlink:href="pone.0161256.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Description</th><th align="left" rowspan="1" colspan="1">P-value</th><th align="left" rowspan="1" colspan="1">FDR q-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Cytokine-cytokine receptor interaction</td><td align="left" rowspan="1" colspan="1">1.50E-05</td><td align="left" rowspan="1" colspan="1">1.40E-03</td></tr><tr><td align="left" rowspan="1" colspan="1">MAPK signaling pathway</td><td align="left" rowspan="1" colspan="1">1.50E-05</td><td align="left" rowspan="1" colspan="1">1.40E-03</td></tr><tr><td align="left" rowspan="1" colspan="1">TGF-beta signaling pathway</td><td align="left" rowspan="1" colspan="1">6.61E-04</td><td align="left" rowspan="1" colspan="1">4.10E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">Pyrimidine metabolism</td><td align="left" rowspan="1" colspan="1">9.66E-04</td><td align="left" rowspan="1" colspan="1">4.49E-02</td></tr></tbody></table></alternatives></table-wrap><p>Phenotypic changes in CEA over-expression cells MIP101 clone 8 may be caused by alterations in expression levels of genes, associated with cancer progression and metastasis. <xref ref-type="table" rid="pone.0161256.t003">Table 3</xref> summarizes phenotype-related genes which were selected from the list of differently expressed genes after CEA over-expression.</p><table-wrap id="pone.0161256.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0161256.t003</object-id><label>Table 3</label><caption><title>Phenotype-related genes in MIP101 clone 8 cells with CEA over-expression.</title></caption><alternatives><graphic id="pone.0161256.t003g" xlink:href="pone.0161256.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Gene name</th><th align="left" rowspan="1" colspan="1">Description</th><th align="left" rowspan="1" colspan="1">Log2 fold change</th><th align="left" rowspan="1" colspan="1">P-value</th><th align="left" rowspan="1" colspan="1">FDR</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold><italic>TGFB2</italic></bold></td><td align="left" rowspan="1" colspan="1">transforming growth factor, beta 2</td><td align="left" rowspan="1" colspan="1">2.09</td><td align="left" rowspan="1" colspan="1">1.14E-04</td><td align="left" rowspan="1" colspan="1">1.38E-02</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>VEGFA</italic></bold></td><td align="left" rowspan="1" colspan="1">vascular endothelial growth factor A</td><td align="left" rowspan="1" colspan="1">-2.08</td><td align="left" rowspan="1" colspan="1">1.15E-06</td><td align="left" rowspan="1" colspan="1">2.69E-04</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>CXCL5</italic></bold></td><td align="left" rowspan="1" colspan="1">chemokine (C-X-C motif) ligand 5</td><td align="left" rowspan="1" colspan="1">-8.87</td><td align="left" rowspan="1" colspan="1">2.27E-11</td><td align="left" rowspan="1" colspan="1">1.59E-08</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>TNFSF15</italic></bold></td><td align="left" rowspan="1" colspan="1">tumor necrosis factor (ligand) superfamily, member 15</td><td align="left" rowspan="1" colspan="1">-2.15</td><td align="left" rowspan="1" colspan="1">1.60E-04</td><td align="left" rowspan="1" colspan="1">1.80E-02</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>FGF21</italic></bold></td><td align="left" rowspan="1" colspan="1">fibroblast growth factor 21</td><td align="left" rowspan="1" colspan="1">-4.18</td><td align="left" rowspan="1" colspan="1">2.38E-06</td><td align="left" rowspan="1" colspan="1">5.20E-04</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>GADD45A</italic></bold></td><td align="left" rowspan="1" colspan="1">growth arrest and DNA-damage-inducible, alpha</td><td align="left" rowspan="1" colspan="1">-2.28</td><td align="left" rowspan="1" colspan="1">1.60E-13</td><td align="left" rowspan="1" colspan="1">1.52E-10</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>HSPA1B</italic></bold></td><td align="left" rowspan="1" colspan="1">heat shock 70kDa protein 1B</td><td align="left" rowspan="1" colspan="1">3.24</td><td align="left" rowspan="1" colspan="1">3.06E-10</td><td align="left" rowspan="1" colspan="1">1.75E-07</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>MAP2K6</italic></bold></td><td align="left" rowspan="1" colspan="1">mitogen-activated protein kinase kinase 6</td><td align="left" rowspan="1" colspan="1">-3.75</td><td align="left" rowspan="1" colspan="1">1.70E-04</td><td align="left" rowspan="1" colspan="1">1.90E-02</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>MAGED1</italic></bold></td><td align="left" rowspan="1" colspan="1">melanoma antigen family D, 1</td><td align="left" rowspan="1" colspan="1">2.07</td><td align="left" rowspan="1" colspan="1">1.14E-11</td><td align="left" rowspan="1" colspan="1">8.43E-09</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>KLF11</italic></bold></td><td align="left" rowspan="1" colspan="1">Kruppel-like factor 11</td><td align="left" rowspan="1" colspan="1">-2.61</td><td align="left" rowspan="1" colspan="1">3.25E-05</td><td align="left" rowspan="1" colspan="1">4.77E-03</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec010"><title>Validation of RNA-seq data by qRT-PCR</title><p>We performed qRT-PCR to validate RNA-seq technology and bioinformatics methods. Three up-regulated genes (<italic>DSP</italic>, <italic>PCDH1</italic> and <italic>WFS1</italic>) and two down-regulated genes (<italic>GADD45A</italic> and <italic>KLF11</italic>) were randomly selected from the list of differently expressed genes.</p><p><italic>CEA</italic> gene expression was used as a positive control and <italic>GAPDH</italic> gene was used as an endogenous control. As demonstrated in <xref ref-type="fig" rid="pone.0161256.g003">Fig 3</xref>, the up-regulation and down-regulation of all selected genes were in accordance with RNA-seq analysis results. The results of classic PCR analysis are presented in <xref ref-type="supplementary-material" rid="pone.0161256.s001">S1 Fig</xref>.</p><fig id="pone.0161256.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0161256.g003</object-id><label>Fig 3</label><caption><title>Validation of RNA-Seq results was performed by qRT-PCR analysis on 5 randomly chosen genes from the list of differentially expressed genes.</title><p>CEACAM5 also was analysed as positive control. Results obtained by RNA-Seq and qRT-PCR methods show high accordance. Each qRT-PCR was performed with three replicates. All data are means &#x000b1; SD. (*p &#x0003c; 0.05; **p &#x0003c; 0.01, ***p &#x0003c; 0.001, one-way ANOVA for qRT-PCR and FDR-adjusted exact test for RNA-Seq).</p></caption><graphic xlink:href="pone.0161256.g003"/></fig></sec></sec><sec sec-type="conclusions" id="sec011"><title>Discussion</title><p>The steady growth of cancer incidence, increasing survival ages, and high mortality from cancer metastasis requires the development of more specific and effective methods for diagnostics and prevention of metastasis. Metastasis is the end product of a multi-step, cell-biological process termed the invasion-metastasis cascade which involves dissemination of cancer cells to anatomically distant organs and their subsequent adaptation to a foreign tissue microenvironment. Each of these events is driven by the acquisition of genetic and epigenetic alterations within the tumor cells and multiple interactions between the metastatic population and microenvironment [<xref rid="pone.0161256.ref013" ref-type="bibr">13</xref>]. Metastasis is a highly specific process. Colorectal cancer cells frequently develop metastases to the liver and lungs, whereas prostate and breast cancers more frequently target the bones as their site for metastasis [<xref rid="pone.0161256.ref013" ref-type="bibr">13</xref>].</p><p>Although CEA plays a key role in the formation of hepatic metastasis from colorectal cancer the precise mechanism for CEA-induced metastasis is not yet well understood [<xref rid="pone.0161256.ref014" ref-type="bibr">14</xref>]. We discovered and cloned the gene for the CEA receptor from the liver macrophages&#x02014;Kupffer cells [<xref rid="pone.0161256.ref015" ref-type="bibr">15</xref>]. It has been shown that the CEA/CEAR interaction on the surface of Kupffer cells stimulates the IL1a, IL6, IL10 and TNF-alpha cytokine production and influences the cell adhesion molecules in the liver that enhances the survival and homing of metastatic cancer cells in the liver that trigger metastasis [<xref rid="pone.0161256.ref016" ref-type="bibr">16</xref>].</p><p>In this study we carried out an in-depth analysis on the effect of CEA on colorectal cancer cells. The new information on the gene expression, biological processes and signaling pathways involved in response to CEA were elucidated. The transcriptomic profiling revealed changes in the level of expression for 100 genes (<xref ref-type="fig" rid="pone.0161256.g001">Fig 1</xref>) including <italic>VEGFA</italic>, <italic>CXCL5</italic>, <italic>TNFSF15</italic>, <italic>PCDH1 etc</italic>.</p><p>Previously, we have shown the influence of CEA synthesized by cancer cells on the formation and function of E-cadherin adhesion junction complexes [<xref rid="pone.0161256.ref008" ref-type="bibr">8</xref>]. These complexes are one of the main contacts between the epithelial cells. CEA disrupts the interactions between the proteins that form these complexes: E-cadherin, alpha- and beta-catenins, and catenin p120. CEA production also changed the splicing variants of catenin p120 protein and triggered the nuclear expression of beta-catenin [<xref rid="pone.0161256.ref008" ref-type="bibr">8</xref>]. P120-catenin is a master regulator of cadherin stability and a modulator of Rho GTPase activity. Although p120-catenin stabilizes E-cadherin at the plasma membrane and promotes cell-cell adhesion, it can also promote cell motility and invasion [<xref rid="pone.0161256.ref017" ref-type="bibr">17</xref>].</p><p>Using the Gene Ontology (GO) enrichment analysis we discovered 49 GO biological processes that were functionally enriched by CEA including cell proliferation, apoptosis, response to stress, transcription and nucleic acid metabolism (<xref ref-type="table" rid="pone.0161256.t001">Table 1</xref>). First, CEA receptor protein (CEAR) has been described as heterogeneous nuclear RNA-binding protein M (HNRNPM1-4) [<xref rid="pone.0161256.ref018" ref-type="bibr">18</xref>]. This protein belongs to a large family of heterogeneous nuclear RNA-binding proteins (HNRNPs A-U), also called &#x0201c;histones of RNA&#x0201d; [<xref rid="pone.0161256.ref018" ref-type="bibr">18</xref>]. It is an abundant nuclear shuttling protein that has at least 4 protein isoforms [<xref rid="pone.0161256.ref018" ref-type="bibr">18</xref>] and only 2 transcripts have been experimentally validated: the full-length protein (isoform 1) and the short form (isoform 2) that has a deletion [<xref rid="pone.0161256.ref019" ref-type="bibr">19</xref>]. We identified the isoform 2 as the CEA-binding protein on the surface of Kupffer cells [<xref rid="pone.0161256.ref020" ref-type="bibr">20</xref>].</p><p>The HNRNPM is a multifunctional protein that is involved in mRNA processing [<xref rid="pone.0161256.ref021" ref-type="bibr">21</xref>] and splicing [<xref rid="pone.0161256.ref022" ref-type="bibr">22</xref>]. In human cells, CEAR/ HNRNPM plays a role in regulating FGFR2 alternative splicing and can affect the splicing of several other genes [<xref rid="pone.0161256.ref023" ref-type="bibr">23</xref>].</p><p>Post-transcriptional modifications can modulate HNRNPM activity by altering its localization, its RNA binding specificity, and interaction with other cellular factors [<xref rid="pone.0161256.ref019" ref-type="bibr">19</xref>]. Generally, HNRNPM has a diffuse nuclear distribution and remains bound to the mRNA as it is transported through nuclear pores. Using isoform specific antibodies, we have shown that in macrophages and colorectal cancer cells the full-length HNRNPM protein-isoform 1 is localized in the nucleus versus the short isoform 2, which appears in the cytoplasm and on the surface of the cells [<xref rid="pone.0161256.ref020" ref-type="bibr">20</xref>].</p><p>In support of our data, new evidence has emerged regarding CEA/CEAR signaling pathway activation in the endothelial cells [<xref rid="pone.0161256.ref024" ref-type="bibr">24</xref>]. Endothelial cells do not synthesize CEA. However, soluble CEA, produced by cancer cells, binds with the CEAR receptor on the endothelial cells. Importantly, down-regulation of HNRNPM /CEAR and not VEGF in endothelial cells suppresses tumor angiogenesis [<xref rid="pone.0161256.ref024" ref-type="bibr">24</xref>]. Clinical research also shown that up-regulation of HNRNPM/CEAR protein is associated with the aggressive types of colon [<xref rid="pone.0161256.ref025" ref-type="bibr">25</xref>] and breast cancers [<xref rid="pone.0161256.ref022" ref-type="bibr">22</xref>]. Together, these results elucidate a novel function for CEA/CEAR signaling in the tumor angiogenesis and metastasis.</p><p>Using RNA sequencing we performed KEGG analysis and identified 4 new significantly enriched by CEA over-expression pathways: cytokine-cytokine receptor interaction, MAPK signaling pathway, TGF-beta signaling pathway and pyrimidine metabolism (see <xref ref-type="table" rid="pone.0161256.t002">Table 2</xref>).</p><p>The transforming growth factor-&#x003b2; (TGF-&#x003b2;) signaling pathway is involved in the control of multiple cancer-related biological processes, including cell proliferation, differentiation, migration, and apoptosis. TGF-&#x003b2; and CEA signaling also induce the epithelial-mesenchymal transition that is essential for metastasis in tumor cells. Recently it has been reported that TGF-&#x003b2; may signal through HNRNPM/CEAR [<xref rid="pone.0161256.ref026" ref-type="bibr">26</xref>]. The authors suggested that NF-kappaB could be a common point between these pathways [<xref rid="pone.0161256.ref026" ref-type="bibr">26</xref>]. Our data also show that MAPK pathway is deregulated by CEA overexpression. MAPK signaling pathway is closely related to the TGF-&#x003b2; signaling pathway.</p><p>In this study the large-scale RNA sequencing analysis has provided a wealth of information on the biologically relevant systems that are involved in the response to CEA. We identified the key signaling pathways and proteins that are involved in the CEA-induced colorectal cancer. It represents a major step toward the understanding of the mechanism of colorectal cancer hepatic metastasis.</p><p>A successful design of novel therapeutic regimens to target CEA producing cancers is only possible if the network-based pathways are correctly identified. Uncovering the underlying molecular mechanisms of CEA/CEAR signaling in angiogenesis and metastasis will lead to the development of new therapeutic possibilities and agents to suppress the CEA expression and to prevent metastasis.</p></sec><sec sec-type="supplementary-material" id="sec012"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0161256.s001"><label>S1 Fig</label><caption><p>(DOCX)</p></caption><media xlink:href="pone.0161256.s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0161256.s002"><label>S1 Table</label><caption><p>(DOCX)</p></caption><media xlink:href="pone.0161256.s002.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0161256.s003"><label>S2 Table</label><caption><p>(DOCX)</p></caption><media xlink:href="pone.0161256.s003.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0161256.s004"><label>S3 Table</label><caption><p>(DOCX)</p></caption><media xlink:href="pone.0161256.s004.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We thank Dr. Peter Thomas (Creighton University, Omaha, USA) for providing the MIP101 cell lines. We also thank Dr. S. Simonov (Theodosius Dobzhansky Center for Genome Bioinformatics at St. Petersburg State University) for useful advice in the data analysis and E. Tkach (University of Massachusetts at Amherst) for the careful proof reading of our manuscript and valuable suggestions.</p></ack><ref-list><title>References</title><ref id="pone.0161256.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Siegel</surname><given-names>R</given-names></name>, <name><surname>Desantis</surname><given-names>C</given-names></name>, <name><surname>Jemal</surname><given-names>A</given-names></name>. <article-title>Colorectal cancer statistics</article-title>. <source>CA Cancer J Clin</source>. <year>2014</year>; <volume>64</volume>: <fpage>104</fpage>&#x02013;<lpage>117</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3322/caac.21220">10.3322/caac.21220</ext-link></comment>
<?supplied-pmid 24639052?><pub-id pub-id-type="pmid">24639052</pub-id></mixed-citation></ref><ref id="pone.0161256.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Locker</surname><given-names>GY</given-names></name>, <name><surname>Hamilton</surname><given-names>S</given-names></name>, <name><surname>Harris</surname><given-names>J</given-names></name>, <name><surname>Jessup</surname><given-names>JM</given-names></name>, <name><surname>Kemeny</surname><given-names>N</given-names></name>, <name><surname>Macdonald</surname><given-names>JS</given-names></name>, <etal>et al</etal>
<article-title>ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer</article-title>. <source>J Clin Oncol</source>. <year>2006</year>; <volume>24</volume>: <fpage>5313</fpage>&#x02013;<lpage>5327</lpage>. <?supplied-pmid 17060676?><pub-id pub-id-type="pmid">17060676</pub-id></mixed-citation></ref><ref id="pone.0161256.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Duffy</surname><given-names>MJ</given-names></name>, <name><surname>Lamerz</surname><given-names>R</given-names></name>, <name><surname>Haglund</surname><given-names>C</given-names></name>, <name><surname>Nicolini</surname><given-names>A</given-names></name>, <name><surname>Kalousov&#x000e1;</surname><given-names>M</given-names></name>, <name><surname>Holubec</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update</article-title>. <source>Int J Cancer</source>. <year>2014</year>; <volume>134</volume>: <fpage>2513</fpage>&#x02013;<lpage>2522</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ijc.28384">10.1002/ijc.28384</ext-link></comment>
<?supplied-pmid 23852704?><pub-id pub-id-type="pmid">23852704</pub-id></mixed-citation></ref><ref id="pone.0161256.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Malati</surname><given-names>T</given-names></name>. <article-title>Tumour markers: An overview</article-title>. <source>Indian J Clin Biochem</source>. <year>2007</year>; <volume>22</volume>: <fpage>17</fpage>&#x02013;<lpage>31</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/BF02913308">10.1007/BF02913308</ext-link></comment>
<?supplied-pmid 23105677?><pub-id pub-id-type="pmid">23105677</pub-id></mixed-citation></ref><ref id="pone.0161256.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Pavlopoulou</surname><given-names>A</given-names></name>, <name><surname>Scorilas</surname><given-names>A</given-names></name>. <article-title>A Comprehensive Phylogenetic and Structural Analysis of the Carcinoembryonic Antigen (CEA) Gene Family Genome</article-title>. <source>Biol Evol</source>. <year>2014</year>; <volume>6</volume>: <fpage>1314</fpage>&#x02013;<lpage>1326</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/gbe/evu103">10.1093/gbe/evu103</ext-link></comment></mixed-citation></ref><ref id="pone.0161256.ref006"><label>6</label><mixed-citation publication-type="book"><name><surname>Jessup</surname><given-names>JM</given-names></name>, <name><surname>Thomas</surname><given-names>P</given-names></name>. <chapter-title>CEA and metastasis: a facilitator of site specific metastasis</chapter-title> In: <source>Cell Adhesion and Communication Mediated by the CEA Family: Basic and Clinical Perspectives</source>. <name><surname>Stanners</surname><given-names>C.P.</given-names></name>, ed., <year>1998</year>
<publisher-name>Harwood Academic Publishers</publisher-name>, <publisher-loc>Amsterdam, Netherlands</publisher-loc> pp <fpage>195</fpage>&#x02013;<lpage>222</lpage>.</mixed-citation></ref><ref id="pone.0161256.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Ordo&#x000f1;ez</surname><given-names>C</given-names></name>, <name><surname>Screaton</surname><given-names>RA</given-names></name>, <name><surname>Ilantzis</surname><given-names>C</given-names></name>, <name><surname>Stanners</surname><given-names>CP</given-names></name>. <article-title>Human carcinoembryonic antigen functions as a general inhibitor of anoikis</article-title>. <source>Cancer Res</source>. <year>2000</year>; <volume>60</volume>: <fpage>3419</fpage>&#x02013;<lpage>3424</lpage>. <?supplied-pmid 10910050?><pub-id pub-id-type="pmid">10910050</pub-id></mixed-citation></ref><ref id="pone.0161256.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Bajenova</surname><given-names>O</given-names></name>, <name><surname>Chaika</surname><given-names>N</given-names></name>, <name><surname>Tolkunova</surname><given-names>E</given-names></name>, <name><surname>Davydov-Sinitsyn</surname><given-names>A</given-names></name>, <name><surname>Gapon</surname><given-names>S</given-names></name>, <name><surname>Thomas</surname><given-names>P</given-names></name>, <name><surname>O'Brien</surname><given-names>SJO</given-names></name>. <article-title>Carcinoembryonic antigen promotes colorectal cancer progression by targeting adherens junction complexes</article-title>. <source>Exp Cell Res</source>. <year>2014</year>; <volume>324</volume>: <fpage>115</fpage>&#x02013;<lpage>123</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.yexcr.2014.04.007">10.1016/j.yexcr.2014.04.007</ext-link></comment>
<?supplied-pmid 24726916?><pub-id pub-id-type="pmid">24726916</pub-id></mixed-citation></ref><ref id="pone.0161256.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Hostetter</surname><given-names>RB</given-names></name>, <name><surname>Augustus</surname><given-names>LB</given-names></name>, <name><surname>Mankarious</surname><given-names>R</given-names></name>, <name><surname>Chi</surname><given-names>K</given-names></name>, <name><surname>Fan</surname><given-names>D</given-names></name>, <name><surname>Toth</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Carcinoembryonic antigen as a selective enhancer of colorectal cancer metastasis</article-title>. <source>J Natl Cancer Inst</source>. <year>1990</year>; <volume>82</volume>: <fpage>380</fpage>&#x02013;<lpage>385</lpage>. <?supplied-pmid 2304087?><pub-id pub-id-type="pmid">2304087</pub-id></mixed-citation></ref><ref id="pone.0161256.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Williams</surname><given-names>AG</given-names></name>, <name><surname>Thomas</surname><given-names>S</given-names></name>, <name><surname>Wyman</surname><given-names>SK</given-names></name>, <name><surname>Holloway</surname><given-names>AK</given-names></name>. <article-title>RNA-seq Data: Challenges in and Recommendations for Experimental Design and Analysis</article-title>. <source>Curr Protoc Hum Genet</source>. <year>2014</year>; <month>10</month>
<day>1</day>;<volume>83</volume>:<fpage>11.13.1</fpage>&#x02013;<lpage>11.13.20</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/0471142905.hg1113s83">10.1002/0471142905.hg1113s83</ext-link></comment><pub-id pub-id-type="pmid">25271838</pub-id></mixed-citation></ref><ref id="pone.0161256.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Trapnell</surname><given-names>C</given-names></name>, <name><surname>Roberts</surname><given-names>A</given-names></name>, <name><surname>Goff</surname><given-names>L</given-names></name>, <name><surname>Pertea</surname><given-names>G</given-names></name>, <name><surname>Kim</surname><given-names>D</given-names></name>, <name><surname>Kelley</surname><given-names>DR</given-names></name>, <etal>et al</etal>
<article-title>Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks</article-title>. <source>Nat Protoc</source>. <year>2012</year>; <volume>7</volume>: <fpage>562</fpage>&#x02013;<lpage>578</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nprot.2012.016">10.1038/nprot.2012.016</ext-link></comment>
<?supplied-pmid 22383036?><pub-id pub-id-type="pmid">22383036</pub-id></mixed-citation></ref><ref id="pone.0161256.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Robinson</surname><given-names>MD</given-names></name>, <name><surname>McCarthy</surname><given-names>DJ</given-names></name>, <name><surname>Smyth</surname><given-names>GK</given-names></name>. <article-title>edgeR: a Bioconductor package for differential expression analysis of digital gene expression data</article-title>. <source>Bioinformatics</source>. <year>2010</year>; <volume>26</volume>: <fpage>139</fpage>&#x02013;<lpage>140</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/bioinformatics/btp616">10.1093/bioinformatics/btp616</ext-link></comment>
<?supplied-pmid 19910308?><pub-id pub-id-type="pmid">19910308</pub-id></mixed-citation></ref><ref id="pone.0161256.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Langley</surname><given-names>RR</given-names></name>, <name><surname>Fidler</surname><given-names>IJ</given-names></name>. <article-title>The seed and soil hypothesis revisited&#x02014;the role of tumor-stroma interactions in metastasis to different organs</article-title>. <source>Int J Cancer</source>. <year>2011</year>; <volume>128</volume>: <fpage>2527</fpage>&#x02013;<lpage>2535</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ijc.26031">10.1002/ijc.26031</ext-link></comment>
<?supplied-pmid 21365651?><pub-id pub-id-type="pmid">21365651</pub-id></mixed-citation></ref><ref id="pone.0161256.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Paschos</surname><given-names>KA</given-names></name>, <name><surname>Majeed</surname><given-names>AW</given-names></name>, <name><surname>Bird</surname><given-names>NC</given-names></name>. <article-title>Natural history of hepatic metastases from colorectal cancer&#x02014;pathobiological pathways with clinical significance</article-title>. <source>World J Gastroenterol</source>. <year>2014</year>; <volume>20</volume>: <fpage>3719</fpage>&#x02013;<lpage>3737</lpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3748/wjg.v20.i14.3719">10.3748/wjg.v20.i14.3719</ext-link></comment>
<?supplied-pmid 24744570?><pub-id pub-id-type="pmid">24744570</pub-id></mixed-citation></ref><ref id="pone.0161256.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Bajenova</surname><given-names>OV</given-names></name>, <name><surname>Zimmer</surname><given-names>R</given-names></name>, <name><surname>Stolper</surname><given-names>E</given-names></name>, <name><surname>Salisbury-Rowswell</surname><given-names>J</given-names></name>, <name><surname>Nanji</surname><given-names>A</given-names></name>, and <name><surname>Thomas</surname><given-names>P</given-names></name>. <article-title>Heterogeneous RNA-binding protein M4 is a receptor for carcinoembryonic antigen in Kupffer cells</article-title>. <source>J Biol Chem</source>. <year>2001</year>; <volume>276</volume>: <fpage>31067</fpage>&#x02013;<lpage>31073</lpage>. <?supplied-pmid 11406629?><pub-id pub-id-type="pmid">11406629</pub-id></mixed-citation></ref><ref id="pone.0161256.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Thomas</surname><given-names>P</given-names></name>, <name><surname>Forse</surname><given-names>&#x00410;</given-names></name>, <name><surname>Bajenova</surname><given-names>O</given-names></name>. <article-title>Carcinoembryonic antigen (CEA) and its receptor hnRNP M are mediators of metastasis and the inflammatory response in the liver</article-title>. <source>Clin Exp Metastasis</source>. <year>2011</year>; <volume>28</volume>: <fpage>923</fpage>&#x02013;<lpage>932</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10585-011-9419-3">10.1007/s10585-011-9419-3</ext-link></comment>
<?supplied-pmid 21901530?><pub-id pub-id-type="pmid">21901530</pub-id></mixed-citation></ref><ref id="pone.0161256.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Yanagisawa</surname><given-names>M</given-names></name>, <name><surname>Huveldt</surname><given-names>D</given-names></name>, <name><surname>Kreinest</surname><given-names>P</given-names></name>, <name><surname>Lohse</surname><given-names>CM</given-names></name>, <name><surname>Cheville</surname><given-names>JC</given-names></name>, <name><surname>Parker</surname><given-names>AS</given-names></name>, <etal>et al</etal>
<article-title>A p120 catenin isoform switch affects Rho activity, induces tumor cell invasion, and predicts metastatic disease</article-title>. <source>J Biol Chem</source>. <year>2008</year>; <volume>283</volume>: <fpage>18344</fpage>&#x02013;<lpage>54</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/jbc.M801192200">10.1074/jbc.M801192200</ext-link></comment>
<?supplied-pmid 18407999?><pub-id pub-id-type="pmid">18407999</pub-id></mixed-citation></ref><ref id="pone.0161256.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Krecic</surname><given-names>AM</given-names></name>, <name><surname>Swanson</surname><given-names>MS</given-names></name>. <article-title>HnRNP complexes: composition, structure, and function</article-title>. <source>Curr Opin Cell Biol</source>. <year>1999</year>; <volume>11</volume>: <fpage>363</fpage>&#x02013;<lpage>371</lpage>. <?supplied-pmid 10395553?><pub-id pub-id-type="pmid">10395553</pub-id></mixed-citation></ref><ref id="pone.0161256.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Marko</surname><given-names>M</given-names></name>, <name><surname>Leichter</surname><given-names>M</given-names></name>, <name><surname>Patrinou-Georgoula</surname><given-names>M</given-names></name>, <name><surname>Guialis</surname><given-names>A</given-names></name>. <article-title>Selective interactions of hnRNP M isoforms with the TET proteins TAF15 and TLS/FUS</article-title>. <source>Mol Biol Rep</source>. <year>2014</year>; <volume>41</volume>: <fpage>2687</fpage>&#x02013;<lpage>2695</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s11033-014-3128-3">10.1007/s11033-014-3128-3</ext-link></comment>
<?supplied-pmid 24474660?><pub-id pub-id-type="pmid">24474660</pub-id></mixed-citation></ref><ref id="pone.0161256.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Bajenova</surname><given-names>O</given-names></name>, <name><surname>Stolper</surname><given-names>E</given-names></name>, <name><surname>Gapon</surname><given-names>S</given-names></name>, <name><surname>Sundina</surname><given-names>N</given-names></name>, <name><surname>Zimmer</surname><given-names>R</given-names></name>, <name><surname>Thomas</surname><given-names>P</given-names></name>. <article-title>Surface expression of HnRNP M4 nuclear protein on Kupffer cells relates to its function as a carcinoembryonic antigen receptor</article-title>. <source>Exp Cell Res</source>. <year>2003</year>; <volume>292</volume>: <fpage>282</fpage>&#x02013;<lpage>291</lpage>. PMID: 14597422</mixed-citation></ref><ref id="pone.0161256.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Hessle</surname><given-names>V</given-names></name>, <name><surname>Bj&#x000f6;rk</surname><given-names>P</given-names></name>, <name><surname>Sokolowski</surname><given-names>M</given-names></name>, <name><surname>Gonz&#x000e1;lez de Valdivia</surname><given-names>E</given-names></name>, <name><surname>Silverstein</surname><given-names>R</given-names></name>, <name><surname>Artemenko</surname><given-names>K</given-names></name>. <article-title>The exosome associates cotranscriptionally with the nascent pre-mRNP through interactions with heterogeneous nuclear ribonucleoproteins</article-title>. <source>Mol Biol Cell</source>. <year>2009</year>; <volume>20</volume>: <fpage>3459</fpage>&#x02013;<lpage>3470</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1091/mbc.E09-01-0079">10.1091/mbc.E09-01-0079</ext-link></comment>
<?supplied-pmid 19494042?><pub-id pub-id-type="pmid">19494042</pub-id></mixed-citation></ref><ref id="pone.0161256.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Xu</surname><given-names>Y</given-names></name>, <name><surname>Gao</surname><given-names>XD</given-names></name>, <name><surname>Lee</surname><given-names>JH</given-names></name>, <name><surname>Huang</surname><given-names>H</given-names></name>, <name><surname>Tan</surname><given-names>H</given-names></name>, <name><surname>Ahn</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Cell type-restricted activity of hnRNPM promotes breast cancer metastasis via regulating alternative splicing</article-title>. <source>Genes Dev</source>. <year>2014</year>; <volume>28</volume>: <fpage>1191</fpage>&#x02013;<lpage>1203</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1101/gad.241968.114">10.1101/gad.241968.114</ext-link></comment>
<?supplied-pmid 24840202?><pub-id pub-id-type="pmid">24840202</pub-id></mixed-citation></ref><ref id="pone.0161256.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Warzecha</surname><given-names>CC</given-names></name>, <name><surname>Carstens</surname><given-names>RP</given-names></name>. <article-title>Complex changes in alternative pre-mRNA splicing play a central role in the Epithelial-Mesenchymal Transition (EMT)</article-title>
<source>Semin Cancer Biol</source>. <year>2012</year>; <volume>22</volume>(<issue>5&#x02013;6</issue>): <fpage>417</fpage>&#x02013;<lpage>427</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.semcancer.2012.04.003">10.1016/j.semcancer.2012.04.003</ext-link></comment>
<?supplied-pmid 22548723?><pub-id pub-id-type="pmid">22548723</pub-id></mixed-citation></ref><ref id="pone.0161256.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Bramswig</surname><given-names>KH</given-names></name>, <name><surname>Poettler</surname><given-names>M</given-names></name>, <name><surname>Unseld</surname><given-names>M</given-names></name>, <name><surname>Wrba</surname><given-names>F</given-names></name>, <name><surname>Uhrin</surname><given-names>P</given-names></name>, <name><surname>Zimmermann</surname><given-names>W</given-names></name>, <etal>et al</etal>
<article-title>Soluble carcinoembryonic antigen activates endothelial cells and tumor angiogenesis</article-title>. <source>Cancer Res</source>. <year>2013</year>; <volume>73</volume>: <fpage>6584</fpage>&#x02013;<lpage>96</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/0008-5472.CAN-13-0123">10.1158/0008-5472.CAN-13-0123</ext-link></comment>
<?supplied-pmid 24121495?><pub-id pub-id-type="pmid">24121495</pub-id></mixed-citation></ref><ref id="pone.0161256.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>S</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>, <name><surname>Duan</surname><given-names>L</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Li</surname><given-names>C</given-names></name>, <name><surname>Liu</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Identification of HnRNP M as a novel biomarker for colorectal carcinoma by quantitative proteomics</article-title>. <source>Am J Physiol Gastrointest Liver Physiol</source>. <year>2014</year>; <volume>306</volume> (<issue>5</issue>): <fpage>G394</fpage>&#x02013;<lpage>403</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1152/ajpgi.00328.2013">10.1152/ajpgi.00328.2013</ext-link></comment>
<?supplied-pmid 24381081?><pub-id pub-id-type="pmid">24381081</pub-id></mixed-citation></ref><ref id="pone.0161256.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Jensen-Jarolim</surname><given-names>E</given-names></name>, <name><surname>Fazekas</surname><given-names>J</given-names></name>, <name><surname>Singer</surname><given-names>J</given-names></name>, <name><surname>Hofstetter</surname><given-names>G</given-names></name>, <name><surname>Oida</surname><given-names>K</given-names></name>, <name><surname>Matsuda</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Crosstalk of carcinoembryonic antigen and transforming growth factor-&#x003b2; via their receptors: comparing human and canine cancer</article-title>. <source>Cancer Immunol Immunother</source>. <year>2015</year>; <volume>64</volume>: <fpage>531</fpage>&#x02013;<lpage>537</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00262-015-1684-6">10.1007/s00262-015-1684-6</ext-link></comment>
<?supplied-pmid 25832000?><pub-id pub-id-type="pmid">25832000</pub-id></mixed-citation></ref></ref-list></back></article>